key: cord-0812611-haz2nqkd
authors: Yin, Xin; Ye, Qi‐Qing; Wu, Ke‐Fan; Zeng, Ji‐Yuan; Li, Nan‐Xi; Mo, Jun‐Jian; Huang, Pei‐Ying; Xie, Li‐Min; Xie, Li‐Ying; Guo, Xu‐Guang
title: Diagnostic value of Lipoarabinomannan antigen for detecting Mycobacterium tuberculosis in adults and children with or without HIV infection
date: 2022-01-16
journal: J Clin Lab Anal
DOI: 10.1002/jcla.24238
sha: 431d69c820f1fc48eda134186f8596a0a81d0c8a
doc_id: 812611
cord_uid: haz2nqkd

OBJECTIVES: Even today, tuberculosis (TB) remains a leading public health problem; yet, the current diagnostic methods still have a few shortcomings. Lipoarabinomannan (LAM) provides an opportunity for TB diagnosis, and urine LAM detection seems to have a promising and widely applicable prospect. DESIGN OR METHODS: Four databases were systematically searched for eligible studies, and the quality of the studies was evaluated using the quality assessment of diagnostic accuracy studies‐2 (QUADAS‐2). Graphs and tables were created to show sensitivity, specificity, likelihood ratios, diagnostic odds ratio (DOR), the area under the curve (AUC), and so on. RESULTS: Based on the included 67 studies, the pooled sensitivity of urine LAM was 48% and specificity was 89%. In the subgroup analyses, the FujiLAM test had higher sensitivity (69%) and specificity (92%). Furthermore, among patients infected with human immunodeficiency virus (HIV), 50% of TB patients were diagnosed using a urine LAM test. Besides, the CD4+ cell count was inversely proportional to the sensitivity. CONCLUSIONS: Urine LAM is a promising diagnostic test for TB, particularly using the FujiLAM in HIV‐infected adults whose CD4+ cell count is ≤100 per μl. Besides, the urine LAM test shows various sensitivities and specificities in different subgroups in terms of age, HIV infection status, CD4+ cell count, and testing method.

Bacterial culture is a common method for diagnosing TB. 5 The culture can be obtained successfully for a vast majority of patients.

However, the process consumes a disproportionate amount of time. 6 Currently, Xpert MTB/RIF is widely used in molecular diagnostic testing due to its ability to rapidly identify Mycobacterium tuberculosis (MTB). 6 However, several limitations have been observed for this method. Although published data demonstrated Xpert's improved smear microscopy accuracy, patients must provide adequate quality and volume sputum samples. 7 Xpert's inflated cost is also seen as a major impediment to its implementation. 8 That is why we urgently require advanced tests that are accurate, rapid, inexpensive, and simple.

Lipoarabinomannan (LAM), a cell surface-associated glycolipid component, was found in the MTB cell wall, which has been the most common antigen for MTB detection. 9, 10 At present, the commonly used LAM detection includes the enzyme-linked immunosorbent assay (ELISA), Determine LAM assay, 11 and Fujifilm SILVAMP TB LAM (FujiLAM). In addition, unlike sputum, urine is determined to be easy to obtain and store, noninvasive, and has a lower risk of nosocomial transmission. 12 In this study, we perform a meta-analysis based on the pooled eligible studies. Subgroup analyses, particularly regarding HIV status and detection methods, were settled after a recent review revealed that they increased heterogeneity. 13 The purpose is to assess the diagnostic accuracy of urine LAM antigen testing for MTB in urine specimens, laying the foundation for clinical prevention and control decision-making.

The electronic databases, including PubMed, Embase, Cochrane Library, and Web of Science, were searched using the key terms "Mycobacterium tuberculosis" "lipoarabinomannan" as detailed in Table S1 . Embase EmTree and PubMed MeSH were utilized to broaden synonyms. All papers were published from September 1986 to September 2020 and scrutinized by two reviewers independently.

The study protocol was registered as CRD42021273056 in PROSPERO which is an international prospective register of systematic reviews (https://www.crd.york.ac.uk/prosp ero/). The PRISMA Statement guidelines were followed in all of our review processes (http://www.prism a-state ment.org/).

Before data extraction, the study's inclusion and exclusion criteria were prespecified. The criteria for inclusion in the reviewed studies were as follows: (i) participants were patients with suspected or diagnosed TB; (ii) the diagnostic method was based on lipoarabinomannan; (iii) the urine sample was used; (iv) the diagnostic accuracy was achieved using a gold standard method; (v) the data provided by the study could identify true positive (TP), false positive (FP), true negative (TN), false negative (FN), sensitivity, and specificity; and (vi) English literature was included.

The exclusion criteria were as follows: (i) duplicate or overlapping publications; (ii) review articles, editorials, conference abstracts, letters, case reports, etc.; (iii) studies that were preprinted only; (iv) sensitivity or specificity is unclear. The researchers used EndNote version X9 (Thomson Corporation, Stamford, CT, USA) to sort out eligible studies with the predetermined screening.

Six reviewers working in pairs screened and extracted data independently. When two reviewers' opinions differed, a third reviewer was consulted to reach a final decision. Two reviewers independently extracted all of the following information from all incorporated publications using a standardized form: first author, publication year, country, study group, sample size, detection method, reference standard, HIV status, CD4+ cell count, TP, FP, TN, and FN.

Quality Assessment of Diagnostic Accuracy Study 2 (QUADAS-2) 

Meta-regression and subgroup analyses were carried out based on various independent variables: age (children or adults), HIV status (positive or negative), detection test (ELISA, Determine TB assay, or FujiLAM), reference test (culture or composite reference standard), pulmonary tuberculosis (PTB) (yes or no), and CD4+ cell count, etc.

Using Meta-DiSc version 1.4 (Clinical Biostatistics Unit, Madrid, Spain) software, 15 we independently analyzed the data, including sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), the area under the curve (AUC), and their 95% confidence intervals (CIs). Moreover, heterogeneity was assessed by the inconsistency index I 2 , for which both threshold effect and nonthreshold effect are responsible. The Spearman correlation was used to determine whether there was a threshold effect, as a strong correlation showed a threshold effect.

The P-value of the DOR plot was computed to ascertain the nonthreshold effect.

Effect models were determined based on the degree of heterogeneity among studies. If the heterogeneity was not significant (I 2 < 75%), a fixed-effect model could be chosen to analyze the results. If significant heterogeneity (I 2 ≥ 75%) existed, a random-effect model (DerSimonian-Laird method) was applied.

All analyses were conducted using the Midas package in Stata version 13.0 (Stata Corp, College Station, Texas, USA). A bivariate boxplot was used to assess the heterogeneity in the included studies. The Deeks' funnel plot was verified to confirm publication bias.

After searching databases, the literature search yielded 1622 articles, of which 615 were reduplicative. Following a review of all abstracts and titles, 845 studies were found to be unrelated. Then we went over the text, and 95 studies were eliminated for various reasons. Finally, 67 articles with a total of 164 reports and 23727 samples were included 6,16-81 ( Figure S1 ).

Studies that met our selection criteria are described in Table S2 .

The majority of patients came from African sites, particularly South Africa (33/67, 52.2%). In total, 17 of 67 articles studied PTB, and others looked at PTB and extrapulmonary TB like tuberculous meningitis and lymph node TB.

We evaluated the quality of the included studies, and the summaries according to the QUADAS-2 criteria are shown in Figure 1 and S2. In the field of the index test, reference standard, flow, and timing, more than 90% of studies had a low risk of bias and applicability concerns.

It is worth noting that more than 10% of the studies had high applicability concerns in patient selection because they did not include continuous or random participants.

The overall sensitivity was 48% (95% CI 48%-49%) and specificity was 89% (95% CI 89%-89%), with 94.8% and 95.2% heterogeneity in Figures S3 and S4 , respectively.

In the threshold effect analysis, Spearman correlation coefficient was 0.392 (p < 0.001), indicating a strong positive correlation (Table 1) . Moreover, the distribution of the shoulder-arm points on the summary receiver operating characteristic (SROC) curve indicated the existence of the threshold effect ( Figure 2 ). The threshold effect suggested the difference in judging criteria between diagnostic tests as a result of different thresholds.

In the case of DOR, the Cochran-Q was 946.50 (p < 0.05), indicating that a nonthreshold effect was a potential source of heterogeneity ( Figure S5 ). The nonthreshold effect can be caused by various factors, age, reference standards, testing techniques, and so on. Metaregression was performed and suggested that the nonthreshold effect was most likely due to age, as the diagnostic accuracy of the adult was 4.13 times that of the nonadult.

F I G U R E 1 Pooled bias risks and applicability concerns using the QUADAS-2 criteria

DerSimonian-Laird was used to fit the SROC curve, while the pvalue of b was >0.05, which indicated the SROC curve was symmetrical ( Table 1 ). The AUC was 0.83 (Figure 2) , and the combined DOR was 8.96 (95% CI 7.45 to 10.79), indicating good diagnostic performance ( Figure S5 ). However, since the significant heterogeneity 

The results of subgroup analyses are detailed in Tables 2-5 . The diagnostic sensitivity, specificity, and DOR of children were lower than that of adults. HIV-negative patients had significantly lower sensitivity and DOR than HIV-positive patients, but no difference in specificity. In the acquired immune deficiency syndrome (AIDS) patients, CD4+ cell count less than 100 per cubic millimeter was more sensitive than CD4+ cell count more than 100 (63% vs 29%) but less spe- Except for subgroup CD4+ cell count ≥200 with poor diagnostic performance (AUC < 0.7), the diagnostic accuracy was high (Table 4) .

Postpositive and postnegative probability in children was 70% and 41%, respectively. Besides, a positive value revealed an 89% posttest probability of a correct diagnosis based on FujiLAM detection, whereas a 29% probability of TB patients was ignored but tested negative (Table 5 ).

According to the bivariate boxplot, we found the source of considerable heterogeneity. The heterogeneity may be resulted from the points outside the circle, thus we reviewed papers these points represent in Figure 3 20,64,79 .

The Deeks' funnel plot ( Figure 4 ) was symmetric, which showed that p = 0.69 (>0.1), and therefore, suggests no potential published offset for the included studies.

Throughout the past decade, TB remains a major public health challenge around the world. 82 Therefore, there is a critical need for a clear and rapid diagnosis of TB, guiding drug use, and controlling the development of diseases. 83 With low infection control risks, noninvasive, and convenient sample collection, the urine-based LAM assay was identified as a focus. 84 The urine-based LAM assay, a simple point-of-care test, has been used in the commercial development of rapid detection of MTB. 85 In addition, LAM assay reduces costs over culture and diagnoses patients with extrapulmonary TB with slightly higher accuracy than smear. 86 The detecting efficacy of LAM antigen in serum, sputum, cerebrospinal fluid samples was also evaluated. However, a low number of eligible studies and a great heterogeneity showed insufficient evidence to compare with the urine samples.

In our study, the overall sensitivity was 48% and specific- To explore the reasons for high heterogeneity indicated by I 2 , the threshold effect and the nonthreshold effect analyses should be performed. 15 We found that heterogeneity occurs due to age, HIV status, CD4+ cell count, detection method, and reference standard method.

Subgroup analyses on the positive likelihood ratio (PLR) and negative likelihood ratio (NLR) of urine lipoarabinomannan (LAM) antigen in the diagnosis of tuberculosis The sensitivity and specificity of diagnosing TB suspected adult were higher than that of children (49% vs 37% & 90% vs 80%). As the primary vaccine for TB prevention, the possibility of Bacillus Calmette Guerin (BCG) vaccination cross-reaction in children is greater than in adults, which may result in FP results. 88, 89 Furthermore, children's poor susceptibility to MTB culture may result in falsely low estimates of specificity. 38 In conclusion, the urine LAM test has limited diagnostic efficacy in TB children.

HIV and is the leading cause of death in AIDS patients. 90 The subgroup analyses were set to reduce the heterogeneity, and the bivariate boxplot was used to obtain further in-depth information. Amin's study only included 100 TB patients, so his findings should be interpreted cautiously. 64 Huerga reported the highest sensitivity (81%) and specificity (100%), but only patients with HIVpositive and CD4+ <100 cells/μl were enrolled. 79 Nonetheless, the current study has a few limitations. In terms of research design and quality assessment, not all selected studies are included in a random or continuous manner, which may result in a lack of reasonable sampling methods. The lack of inpatients and outpatients may obscure some meaningful results by ignoring differences in their population characteristics. 11 Furthermore, studies published in all languages were not included (only English included). In conclusion, the evidence from this study suggests that urine LAM antigen may be a promising biomarker for TB, particularly using FujiLAM. The effect on HIV-positive TB patients is encouraging, with advanced HIV diseases benefiting more. This is consistent with the findings in previous research works. 84 However,

considering the clinical effect of the urine LAM test, more research is recommended.

None.

None declared.

All data generated or analyzed during this study are included in this published article.

Xin Yin https://orcid.org/0000-0002-6200-2111

Qi-Qing Ye https://orcid.org/0000-0001-6292-6210

Ke-Fan Wu https://orcid.org/0000-0001-5595-4061

Ji-Yuan Zeng https://orcid.org/0000-0002-6656-3274

Nan-Xi Li https://orcid.org/0000-0002-9100-8328

Jun-Jian Mo https://orcid.org/0000-0002-1249-9975

Pei-Ying Huang https://orcid.org/0000-0002-6814-0611

Li-Min Xie https://orcid.org/0000-0002-7880-7475

Xu-Guang Guo https://orcid.org/0000-0003-1302-5234 F I G U R E 4 The Deeks' funnel plot of urine lipoarabinomannan (LAM) antigen in the diagnosis of tuberculosis

WHO global progress report on tuberculosis elimination

World Health Organization

HIV and tuberculosis: a deadly human syndemic

The fight to end tuberculosis must not be forgotten in the COVID-19 outbreak

Accuracy of a novel urine test, Fujifilm SILVAMP tuberculosis lipoarabinomannan, for the diagnosis of pulmonary tuberculosis in children

Diagnosing tuberculosis in hospitalized HIV-infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer?

Evaluation of the Xpert MTB/RIF assay in gastric lavage aspirates for diagnosis of smearnegative childhood pulmonary tuberculosis

Point-of-care diagnosis of tuberculosis: past, present and future

Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV

Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and metaanalysis

Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in-and outpatient data

The QUADAS-2 Tool for the quality assessment of diagnostic accuracy study: An Introduction

Meta-DiSc: a software for meta-analysis of test accuracy data

Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine

Diagnostic evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis centre

Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis

Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study

Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease

Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients

Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis

Diagnostic Accuracy of a Urine Lipoarabinomannan Test for Tuberculosis in Hospitalized Patients in a High HIV Prevalence Setting

Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples

Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis

Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis

Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIVassociated pulmonary tuberculosis before antiretroviral therapy: A descriptive study

Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients

Test Characteristics of Urinary Lipoarabinomannan and Predictors of Mortality among Hospitalized HIV-Infected Tuberculosis Suspects in Tanzania

Utility of quantitative analysis of urine lipoarabinomannan in the diagnosis of tuberculosis

Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons?

Modification of clearview tuberculosis (TB) enzyme-linked immunosorbent assay for tb patients not infected with HIV

Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres

Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newlydiagnosed hiv-infected adults: A prospective, clinic-based study

Predictive value of anemia for tuberculosis in HIV-infected patients in Sub-Saharan Africa: an indication for routine microbiological investigation using new rapid assays

Point-of-care lateral flow assays for tuberculosis and Cryptococcal antigenuria predict death in HIV Infected Adults in Uganda

Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIVinfected adults

Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: A prospective study

Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals

Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana-findings from the DETECT HIV-TB study

The diagnostic targeting of a carbohydrate virulence factor from M

Estimation of D-arabinose by gas chromatography/mass spectrometry as surrogate for mycobacterial lipoarabinomannan in human urine

Predictive and prognostic properties of TB-LAM among HIVpositive patients initiating ART in

Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region: a prospective cohort study

Value of urine Lipoarabinomannan grade and second test for optimizing clinicbased screening for HIV-associated pulmonary tuberculosis

The diagnostic accuracy of urine lipoarabinomannan test for tuberculosis screening in a south african correctional facility

Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania

Predictors for MTB culture-positivity among HIV-infected smear-negative presumptive tuberculosis patients in Uganda: application of new tuberculosis diagnostic technology

Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing

Rapid urine LAM testing improves diagnosis of expectorated smear-negative pulmonary tuberculosis in an HIV-endemic region

Rapid urine lipoarabinomannan assay as a clinic-based screening test for active tuberculosis at HIV diagnosis

Diagnostic accuracy of lateral flow urine LAM assay for TB screening of adults with advanced immunosuppression attending routine HIV care in South Africa

The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis

Effect on mortality of pointof-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial

Comparative performance characteristics of the urine lipoarabinomannan strip test and sputum smear microscopy in hospitalized HIV-infected patients with suspected tuberculosis in Harare

Tuberculosis case finding with combined rapid point-of-care assays (Xpert MTB/RIF and Determine TB LAM) in HIV-positive individuals starting antiretroviral therapy in mozambique

Incremental yield of including determine-TB LAM assay in diagnostic algorithms for hospitalized and ambulatory HIV-positive patients in Kenya

The diagnostic value of urine Lipoarabinomannan (LAM) antigen in childhood tuberculosis

Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays

Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: A prospective cohort

Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity

Utility of urine lipoarabinomannan (LAM) in diagnosing tuberculosis and predicting mortality with and without HIV: prospective TB cohort from the Thailand Big City TB Research Network

The clinical utility of the urinebased lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study

Detection of lipoarabinomannan in urine and serum of HIV-positive and HIV-negative TB suspects using an improved capture-enzyme linked immuno absorbent assay and gas chromatography/mass spectrometry

Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV

Urine Tuberculosis lipoarabinomannan predicts mortality in hospitalized human immunodeficiency virus-infected children

A novel sensitive immunoassay targeting the 5-methylthio-xylofuranose-lipoarabinomannan epitope meets the WHO's performance target for tuberculosis diagnosis

Novel lipoarabinomannan pointof-care tuberculosis test for people with HIV: a diagnostic accuracy study

Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients

Urine lipoarabinomannan (LAM) and antimicrobial usage in seriously-ill HIV-infected patients with sputum smear-negative pulmonary tuberculosis

Prospective cohort study on performance of cerebrospinal fluid (CSF) Xpert MTB/RIF, CSF lipoarabinomannan (LAM) lateral flow assay (LFA), and urine LAM LFA for diagnosis of tuberculous meningitis in Zambia

Lateral flow urine Lipoarabinomannan assay for diagnosis of active tuberculosis in adults with human immunodeficiency virus infection: a prospective cohort study

Real-world performance and interobserver agreement of urine lipoarabinomannan in diagnosing HIV-associated tuberculosis in an emergency center

Ultrasensitive detection of lipoarabinomannan with plasmonic grating biosensors in clinical samples of HIV negative patients with tuberculosis

Combining urine lipoarabinomannan with antibody detection as a simple non-sputumbased screening method for HIV-associated tuberculosis

Accuracy and incremental yield of urine Xpert MTB/RIF Ultra versus Determine TB-LAM for diagnosis of pulmonary tuberculosis

Diagnostic accuracy of a novel and rapid lipoarabinomannan test for diagnosing tuberculosis among people with human immunodeficiency virus

An Optimal Diagnostic Strategy for Tuberculosis in Hospitalized HIV-Infected Patients Using GeneXpert MTB/RIF and Alere Determine TB LAM Ag

Systematic, point-of-care urine lipoarabinomannan (AlerE TB-LAM) assay for diagnosing tuberculosis in severely immunocompromised HIV-positive ambulatory patients

Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study from Malawi

Determine TB-LAM pointof-care tuberculosis assay predicts poor outcomes in outpatients during their first year of antiretroviral therapy in South Africa

Global epidemiology of tuberculosis and progress toward meeting global targets -Worldwide

Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV policy update

Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis

Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults

Generation of mycobacterial lipoarabinomannan-specific monoclonal antibodies and their ability to identify mycobacterium isolates

Manipulation of BCG vaccine: a double-edged sword

Tuberculosis in children: screening, diagnosis and management

Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection